AD 2000 Collaborative Group (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 383, 2105–2115.
Chalmers I., Rounding C. & Lock K. (2003). Descriptive survey of non-commercial randomised controlled trials in the United Kingdom, 1980-2002. British Medical Journal 327, 1017.
Cipriani A., Barbui C. & Geddes J.R. (2005). Suicide, depression, and antidepressants. British Medical Journal 330, 373–374.
Fergusson D., Doucette S., Glass K.C., Shapiro S., Healy D., Hebert P. & Hutton B. (2005). Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. British Medical Journal 330, 396.
Geddes J. (2003). Generating evidence to inform policy and practice: the example of the second generation “atypical” amipsychotics. Schizophrenia Bulletin 29, 105–114.
Geddes J.R. & Cipriani A. (2004). Selective serotonin reuptake inhibitors. British Medical Journal 329, 809–810.
Geddes J.R., Freemantle N., Harrison P.J., & Bebbington P.E. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic review and meta-regression analysis. British Medical Journal 321, 1371–1376.
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Collaborative Group (1990). GISS1-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336, 65–71.
Gunnell D. & Ashby D. (2004). Antidepressants and suicide: what is the balance of benefit and harm. British Medical Journal 329, 34–38.
Gunnell D., Saperia J. & Ashby D. (2005). Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. British Medical Journal 330, 385.
Haynes B. (1999). Can it work? Does it work? Is it worth it?. British Medical Journal 319, 652–653.
Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22.
Hotopf M., Lewis G. & Normand C. (1997). Putting trials on trial - the costs and consequences of small trials in depression: a systematic review of methodology. Journal of Epidemiology & Community Health 51, 354–358.
ISIS-1 Collaborative Group (1985). Randomised trial of intravenous atenolol among 16.027 cases of suspected acute myocardial infarction. Lancet 2, 57–66.
ISIS-2 Collaborative Group (1988). Randomised trial of intravenous streptokinase. oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2, 349–360.
ISIS-3 Collaborative Group (1992). ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339, 753–770.
ISIS-4 Collaborative Group (1995). ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4. Lancet 345, 669–685.
Leff J.P. & Wing J.K. (1971). Trial of maintenance therapy in schizophrenia. British Medical Journal 3, 559–604.
Martinez C, Rietbrock S., Wise L., Ashby D., Chick J., Moseley J., Evans S. & Gunnell D. (2005). Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. British Medical Journal 330, 389.
Medical Research Council (1948). Streptomycin treatment of pulmonary tuberculosis. British Medical Journal 769–773.
Medical Research Council (1965). Clinical trial of the treatment of depressive illness. British Medical Journal 1, 881–886.
Mindham R.H., Howland C. & Shepherd M. (1972). Continuation therapy with tricyclic antidepressants in depressive illness. Lancet 2, 854–855.
National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group (1964). Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 10, 246–261.
Peto R., Collins R. & Gray R. (1993). Large-scale randomized evidence: large, simple trials and overviews of trials. Annals of New York Academy of Science 703, 314–340.
Prescott R.J., Counsell C.E., Gillespie W.J., Grant A.M., Russell I.T., Kiauka S., Colthart I.R., Ross S., Shepherd S.M. & Russell D. (1999). Factors that limit the quality, number and progress of randomised controlled trials. Health Technology Assessment 3, 1–143.
Prien R.F., Caffey E.M. Jr & Klett C.J. (1973a). Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Archives of General Psychiatry 28, 337–341.
Prien R.F., Klett C.J. & Caffey E.M.J. (1973b). Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Archives of General Psychiatry 29, 420–425.
Schwartz D. & Lellouch J. (1967). Explanatory and pragmatic attitudes in therapeutic trials. Journal of Chronic Diseases 20, 637–648.
Thornley B. & Adams C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 1181–1184.
Yusuf S., Collins R. & Peto R. (1984). Why do we need some large, simple randomized trials? Statistics in Medicine 3, 409–422.